Using AI to improve monitoring of Kaposi Sarcoma
Official title: Precision Imaging to Evaluation Kaposi Sarcoma (PRIME-KS)
Run by Washington University School of Medicine · NCT06898203 · Data updated 2026-11-12
This study is testing a new low-cost device that uses AI to help doctors better track and measure Kaposi Sarcoma in patients with darker skin in Uganda and Kenya.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 2 sites (Kisumu and 1 other locations) |
| Status | Recruiting |
| Started | April 10, 2026 |
| Main results expected | November 30, 2028 |
| Study ends | November 30, 2029 |
| Registry record updated | September 21, 2026 |
| Trial ID | NCT06898203 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with histopathology-confirmed Kaposi Sarcoma and at least three skin lesions who are capable of providing informed consent.
✕Probably not a fit
Patients who are not initiating treatment for Kaposi Sarcoma or those who are very ill and require hospitalization may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to enhance the monitoring of Kaposi Sarcoma (KS) in Uganda and Kenya by utilizing a low-cost device called SkinScan3D (SS3D) that employs Artificial Intelligence for accurate measurement of cancer lesions. The study involves gathering feedback from healthcare workers and patients through surveys and design workshops to refine the use of the SS3D tool. By addressing the challenges of manual measurement, particularly for patients with darker skin, the study seeks to improve treatment tracking and outcomes for KS patients.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and equitable monitoring of Kaposi Sarcoma, ultimately improving patient outcomes.
How similar studies have gone: While the use of AI in cancer monitoring is an emerging field, this specific approach to improving KS treatment tracking has not been extensively tested, making it a novel initiative.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria - Aim 2 (Patients): * Adults age ≥18 years old * Histopathology-confirmed Kaposi Sarcoma * At least 3 skin lesions * Capable of informed consent * On treatment for Kaposi Sarcoma Exclusion Criteria - Aim 2 (Patients): * Patients not initiating Kaposi Sarcoma treatment * Very ill patients requiring hospitalization Inclusion Criteria - Aim 3 (Patients): * Adults age ≥18 years old * Histopathology-confirmed Kaposi Sarcoma * Capable of informed consent * Initiating treatment for Kaposi Sarcoma Exclusion Criteria - Aim 3 (Patients): * Patients with Kaposi Sarcoma that participated in Aim 1 or Aim 2 * Prior or ongoing Kaposi Sarcoma treatment
Where it's running
-
Infectious Diseases Institute, Makerere University
Kampala, Uganda Recruiting -
Kenya Medical Research Institute
Kisumu, Kenya Not yet recruiting
Study contacts
- Principal investigator: Thomas Odeny, MBChB, MPH, PhD — Washington University School of Medicine
- Study coordinator: Thomas Odeny, MBChB, MPH, PhD
- Email: odeny@wustl.edu
- Phone: 314-273-3022
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CYT107 (recombinant interleukin-7) to treat Kaposi sarcoma in adults with HIV and poor T‑cell recovery
This trial tests whether CYT107, a laboratory-made interleukin-7, can shrink Kaposi sarcoma tumors in adults with HIV who have poor T‑cell recovery.
-
Using advanced imaging to evaluate Kaposi sarcoma
This study is testing if a special 3D camera can help doctors get better images of Kaposi sarcoma skin lesions in patients to track how well treatments are working.
-
Propranolol for treating Kaposi sarcoma in adults
This trial will test whether the oral beta‑blocker propranolol can shrink Kaposi sarcoma lesions in adults, including people living with HIV.
-
Understanding the natural history of Kaposi Sarcoma
This study looks at how Kaposi Sarcoma affects people with weakened immune systems, like those with HIV, by tracking their symptoms and health over time.
-
Peer support program to improve cancer diagnosis and treatment for young people with HIV in Zambia
This study is testing a peer support program to help young people with HIV in Zambia get diagnosed and treated for cancer more effectively.
-
MQ710 with or without pembrolizumab for advanced skin and other solid tumors
This will test different doses of MQ710, alone or together with pembrolizumab, in adults with advanced or recurrent solid tumors (including skin cancers) to find a safe dose with mild side effects.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.